文献速递类风湿关节炎

利用实验室生物标志物预测类风湿关节炎患者对抗TNF治疗的反应:一项系统综述

Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review.
PubMed 文献 · RMD Open · 2022-01-01

该系统综述检索EMBASE、PubMed和Cochrane Library(CENTRAL),纳入41项研究,提取99种实验室生物标志物的预测准确性数据,计算似然比以判断预测价值。五种生物标志物被研究≥3次,无研究显示强预测关联,仅一项抗CCP研究显示弱阳性关联。结论认为未发现能一致显示(强)预测效果的生物标志物。

要点

  • 41项研究中提取99种实验室生物标志物,仅5种被研究≥3次。
  • 无研究显示强预测关联,仅一项抗CCP研究显示弱阳性关联。
  • 未发现能一致预测TNFi治疗反应的生物标志物。

核心结论

  • 未发现能一致显示(强)预测类风湿关节炎患者对TNFi治疗反应的生物标志物。
  • 鉴于既往预测性生物标志物研究结果令人失望,未来研究应聚焦于探索、组合和验证本综述识别的最有前景的实验室生物标志物,并寻找新的预测因子。
  • 未来研究还应关注预测辅助决策能产生较大影响的情境,即使标志物或模型的预测价值有限。

研究设计与样本

  • 系统综述,检索EMBASE、PubMed和Cochrane Library(CENTRAL),纳入呈现实验室生物标志物预测准确性指标或可计算该指标的研究。
  • 从41项纳入研究中提取99种不同生物标志物的数据。
  • 计算似然比以判断某检测结果是否相关地改变应答概率,似然比2-10和0.5-0.1分别视为弱预测因子,高于10或低于0.1视为强预测因子。
  • 主要关注被研究≥3次的生物标志物。
  • PROSPERO注册号:CRD42021278987。

主要发现

  • 从41项纳入研究中提取了99种不同生物标志物的数据。
  • 被研究≥3次的五种生物标志物为:抗环瓜氨酸肽(CCP)、类风湿因子、TNF-α基因-308多态性、HLA-DRB1基因SE拷贝数和FcGR2A多态性。
  • 无研究显示强预测关联,仅一项关于抗CCP的研究显示弱阳性关联。

关键数值与推荐

  • 似然比2-10和0.5-0.1分别视为弱预测因子。
  • 似然比高于10或低于0.1视为强预测因子。
  • 主要关注被研究≥3次的生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this systematic review, we aim to identify laboratory biomarkers that predict response to tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). METHODS: EMBASE, PubMed and Cochrane Library (CENTRAL) were searched for studies that presented predictive accuracy measures of laboratory biomarkers, or in which these were calculable. Likelihood ratios were calculated in order to determine whether a test result relevantly changed the probability of response. Likelihood ratios between 2-10 and 0.5-0.1 were considered weak predictors, respectively, and ratios above 10 or below 0.1 were considered strong predictors of response. Primary focus was on biomarkers studied ≥3 times. RESULTS: From 41 included studies, data on 99 different biomarkers were extracted. Five biomarkers were studied ≥3 times, being (1) anti-cyclic citrullinated peptide (CCP), (2) rheumatoid factor, (3) -308 polymorphism in the TNF-α gene, (4) SE copies in the HLA-DRB1 gene and (5) FcGR2A polymorphism. No studies showed a strong predictive association and only one study on anti-CCP showed a weak positive association. CONCLUSIONS: No biomarkers were found that consistently showed a (strong) predictive effect for response to TNFi in patients with RA. Given the disappointing yield of previous predictive biomarker research, future studies should focus on exploring, combining and validating the most promising laboratory biomarkers identified in this review, and searching for new predictors. Besides this, they should focus on contexts where prediction-aided decision-making can have a large impact (even with limited predictive value of markers/models). PROSPERO REGISTRATION NUMBER: CRD42021278987.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Wientjes MHM, den Broeder AA, Welsing PMJ, et al. Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review. RMD Open. 2022. PMID: 36597975. doi:10.1136/rmdopen-2022-002570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。